Scott Garrett Purchases 7,736 Shares of HCW Biologics (NASDAQ:HCWB) Stock

HCW Biologics Inc. (NASDAQ:HCWB) Director Scott Garrett bought 7,736 shares of the business’s stock in a transaction that occurred on Wednesday, July 29th. The stock was purchased at an average price of $2.58 per share, for a total transaction of $19,958.88. Following the completion of the acquisition, the director owned 41,644 shares in the company, valued at $107,441.52. This represents a 22.81% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

HCW Biologics Trading Up 1.6%

Shares of HCWB stock opened at $3.20 on Friday. The firm has a fifty day simple moving average of $6.50 and a two-hundred day simple moving average of $5.20. HCW Biologics Inc. has a 12 month low of $1.50 and a 12 month high of $44.10. The firm has a market capitalization of $5.12 million, a PE ratio of -0.06 and a beta of 2.29.

HCW Biologics (NASDAQ:HCWB) last released its quarterly earnings data on Thursday, May 14th. The company reported $0.37 earnings per share for the quarter, beating analysts’ consensus estimates of ($2.64) by $3.01. The firm had revenue of $6.54 million for the quarter, compared to analyst estimates of $6.54 million. HCW Biologics had a negative net margin of 34.73% and a negative return on equity of 486.87%.

Institutional Trading of HCW Biologics

An institutional investor recently bought a new position in HCW Biologics stock. Armistice Capital LLC bought a new stake in HCW Biologics Inc. (NASDAQ:HCWB) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 300,180 shares of the company’s stock, valued at approximately $291,000. Armistice Capital LLC owned 9.15% of HCW Biologics at the end of the most recent reporting period. Institutional investors own 2.96% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on HCWB shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of HCW Biologics in a report on Friday, July 17th. Wall Street Zen upgraded shares of HCW Biologics to a “hold” rating in a report on Saturday, May 23rd. Finally, Maxim Group increased their price objective on shares of HCW Biologics from $12.00 to $30.00 and gave the company a “buy” rating in a research note on Thursday, May 28th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, HCW Biologics currently has an average rating of “Hold” and a consensus price target of $30.00.

About HCW Biologics

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.